Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OP-101
- Development stage
- Preclinical
- Lead developer
- Bios Biotechnology
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Ex-vivo Perfusion
01
Overview
OP-101 is a hemoglobin-based oxygen carrier (HBOC) developed by Bios Biotechnology (Biois) as a medical device for organ preservation and myocardial protection. It is formulated as an ex-vivo perfusion solution designed to deliver oxygen to organs during storage and transport, thereby mitigating ischemic injury and improving organ viability for transplantation. Additionally, it is being investigated for myocardial protection during cardiac arrest. As of the latest reports, OP-101 has completed preclinical animal studies, including biosafety and immunosafety evaluations.
- Other names
- organ preservation solutionHBOC medical device
Beyond the preview
Go deeper on OP-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OP-101.